Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Item
http://www.wikidata.org/entity/Q33391949
Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinCarboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions.Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisPopulation pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Nucleoside analogs: ready to enter the era of precision medicine?Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.Design and synthesis of coumarin-based organoselenium as a new hit for myeloprotection and synergistic therapeutic efficacy in adjuvant therapy.Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: analyses from 18 trials.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines.
P2860

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Item
http://www.wikidata.org/entity/Q33391949
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@ast
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@en
type
label
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@ast
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@en
prefLabel
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@ast
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Factors for hematopoietic toxi ...... carboplatin systemic exposure.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698